New User:

Forgot your password?

Stock Market & Financial Investment News

News For GOL;HNR;MDCO;DSW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
11:58 EDTDSWDSW upgraded to Neutral from Underperform at Sterne Agee
10:12 EDTDSWOptions with decreasing implied volatility
Options with decreasing implied volatility: VNET GME ARWR GMCR SGMS DSW DANG ARUN JMEI MBLY
06:37 EDTDSWDSW price target raised to $37 from $34 at Credit Suisse
Subscribe for More Information
November 25, 2014
15:02 EDTDSWDSW price target to $40 following Q3 results at Goldman
Subscribe for More Information
09:20 EDTDSWOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Signet Jewelers (SIG), up 2.6%... Tiffany (TIF), up 4.8%... Nuance Communications (NUAN), up 5.1%... Brown Shoe (BWS), up 6.6%... Cracker Barrel (CBRL), up 3.1%... Qihoo 360 (QIHU), up 5.8%... DSW (DSW), up 7.3%. ALSO HIGHER: SinoCoking Coal (SCOK), up 27.9% after aboveground facility operating at 100% capacity. DOWN AFTER EARNINGS: Xcerra (XCRA), down 7.4%... Workday (WDAY), down 8.4%... Brocade (BRCD), down 3.8%... Post (POST), down 7.5%. ALSO LOWER: Wet Seal (WTSL), down 15.8% after announcing that it has not set a timetable for review of strategic and financial alternatives... Medgenics (MDGN), down 11.1% after 5.125M share Spot Secondary priced at $4.10... Pandora (P), down 3.7% after being downgraded to Underperform from Market Perform at FBR Capital... Cyberark Software (CYBR), down 3.7% after receiving multiple downgrades.
07:04 EDTDSWDSW authorized additional $50M under share repurchase program
Subscribe for More Information
07:02 EDTDSWDSW raises FY14 adjusted EPS to $1.55-$1.65 from $1.50-$1.65, consensus $1.59
Subscribe for More Information
07:01 EDTDSWDSW reports Q3 comparable sales up 2l.6%
Subscribe for More Information
07:01 EDTDSWDSW reports Q3 adjusted EPS 56c, consensus 52c
Subscribe for More Information
November 24, 2014
15:20 EDTDSWNotable companies reporting before tomorrow's open
Subscribe for More Information
November 20, 2014
14:36 EDTDSWDSW December volatility elevated into Q4 and outlook
Subscribe for More Information
10:02 EDTMDCOOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:41 EDTMDCOThe Medicines Co. upgraded at Credit Suisse
Subscribe for More Information
06:06 EDTMDCOThe Medicines Co. upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
November 19, 2014
10:00 EDTDSWOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:20 EDTDSWDSW upgraded to Positive at Susquehanna
As reported previously, Susquehanna upgraded DSW to Positive from Neutral citing a compelling risk/reward scenario and progress made on recapturing lost margins. The firm raised its price target to $38 from $29 on DSW shares.
06:41 EDTDSWDSW upgraded to Positive from Neutral at Susquehanna
November 16, 2014
13:41 EDTMDCOThe Medicines Co. presents findings from MDCO-216 study
The Medicines Company presented findings from a new Phase 1 study showing that a single infusion of MDCO-216, an investigational lipid-modifying agent, in both healthy and CAD patients, modified key lipid parameters including ApoA-1, phospholipids, HDL, pre-beta 1 HDL and Apo E, markedly increased ABCA1 mediated efflux, a potential marker of reverse cholesterol transport and was well tolerated. The study was presented today as part of a poster session at The American Heart Association’s Annual Scientific Sessions in Chicago. Clinical findings have shown that human carriers of the ApoA-1 Milano variant have a reduced incidence of cardiovascular disease. MDCO-216, currently under development by The Medicines Company, is a complex of recombinant human Apo A1 with phospholipids to emulate an HDL particle. MDCO-216 has the potential to modify atherosclerotic disease by promoting reverse cholesterol transport, and its potential impact on reducing cardiovascular events in acute coronary syndrome, ACS, patients. “This study provides a signal that MDCO-216 is able to modulate lipid parameters consistent with those humans with the ApoA-1 variant, had an important effect on markers of reverse cholesterol transport such as pre-beta1 HDL and ABCA1 mediated efflux, and importantly was well-tolerated,” commented David Kallend, MBBS, Vice President and Global Medical Director for the Lipid Programs at The Medicine Company. “These findings support the continued development of MDCO-216 as a potential treatment to help address a currently unmet need in coronary artery disease patients."
November 14, 2014
16:52 EDTDSWGreenlight Capital gives quarterly update on stakes
Subscribe for More Information
10:33 EDTMDCOThe Medicines Co. to present new data on MDCO-216 at AHA sessions
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use